Kidney Neoplasms Clinical Trial
Official title:
The Association of Marital Status With Kidney Cancer Surgery Morbidity
| NCT number | NCT05526599 |
| Other study ID # | 42746034 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | January 1, 2003 |
| Est. completion date | March 31, 2018 |
| Verified date | September 2022 |
| Source | Beijing Tsinghua Chang Gung Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Retrospective cohort study
| Status | Completed |
| Enrollment | 106752 |
| Est. completion date | March 31, 2018 |
| Est. primary completion date | March 31, 2018 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Surgery was performed for a kidney mass. 2. age >= 18 years 3. "elective" cases 4. Surgery was performed on the day0 or day1 after administration. Exclusion Criteria: 1. ICD codes are not available. 2. Missing value of the primary outcomes and exposure. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Beijing Tsinghua Chang Gung Hospital | Brigham and Women's Hospital |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | surgical complications | Complication rates were based on the Clavien-Dindo classification of surgical complications and divided into four categories: no complications, minor complications (Clavien grades 1, 2), and non-fatal major complications (Clavien grades 3, 4), and mortality (Clavien grade 5). | 90 days after surgery | |
| Secondary | patient disposition | patient disposition was divided into home and none home such as skilled nursing or rehabilitation facility | 90 days after surgery | |
| Secondary | readmission rates | readmission was defined as readmitted into the hospital for any reason | 90 days after surgery |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00678392 -
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT03129724 -
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
|
N/A | |
| Terminated |
NCT01413607 -
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy
|
Phase 4 | |
| Terminated |
NCT00091611 -
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
|
Phase 1 | |
| Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A | |
| Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
| Recruiting |
NCT05184504 -
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
|
||
| Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
| Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
| Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
| Terminated |
NCT01712685 -
Imaging Studies of Kidney Cancer Using 18F-VM4-037
|
Phase 2 | |
| Terminated |
NCT00816686 -
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
|
Phase 1 | |
| Completed |
NCT00537056 -
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
|
N/A | |
| Completed |
NCT00076011 -
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT00226980 -
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
| Recruiting |
NCT03062410 -
Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma
|
N/A | |
| Completed |
NCT02924922 -
Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A |